CHEMOCENTRYX INC's ticker is CCXI and the CUSIP is 16383L106. A total of 120 filers reported holding CHEMOCENTRYX INC in Q2 2019. The put-call ratio across all filers is 2.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $43,654,000 | +97.6% | 845,023 | -5.2% | 0.02% | +100.0% |
| Q2 2022 | $22,096,000 | +62.6% | 891,678 | +59.5% | 0.01% | +125.0% |
| Q1 2022 | $13,587,000 | -3.2% | 558,876 | +45.0% | 0.00% | 0.0% |
| Q4 2021 | $14,033,000 | +296.3% | 385,423 | +86.1% | 0.00% | +300.0% |
| Q3 2021 | $3,541,000 | +20.6% | 207,098 | -5.5% | 0.00% | 0.0% |
| Q2 2021 | $2,936,000 | -87.9% | 219,227 | -53.6% | 0.00% | -87.5% |
| Q1 2021 | $24,222,000 | +1277.0% | 472,715 | +116.5% | 0.01% | +700.0% |
| Q4 2020 | $1,759,000 | -56.2% | 218,313 | -56.1% | 0.00% | -50.0% |
| Q3 2020 | $4,012,000 | +14.6% | 497,809 | +14.6% | 0.00% | +100.0% |
| Q2 2020 | $3,501,000 | -80.6% | 434,381 | -3.3% | 0.00% | -88.9% |
| Q1 2020 | $18,056,000 | +16.8% | 449,387 | +15.0% | 0.01% | +50.0% |
| Q4 2019 | $15,459,000 | +808.3% | 390,853 | +55.7% | 0.01% | +500.0% |
| Q3 2019 | $1,702,000 | -54.6% | 250,960 | -37.8% | 0.00% | 0.0% |
| Q2 2019 | $3,750,000 | – | 403,279 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 8,596,772 | $58,716,000 | 11.42% |
| WASATCH ADVISORS LP | 2,536,928 | $17,327,000 | 0.18% |
| BALYASNY ASSET MANAGEMENT L.P. | 1,810,456 | $12,365,000 | 0.11% |
| BLUE ARROW CAPITAL MANAGEMENT LLC | 140,000 | $956,000 | 0.11% |
| Artal Group S.A. | 400,000 | $2,732,000 | 0.10% |
| Artal Group S.A. | 400,000 | $2,732,000 | 0.10% |
| Gruss Capital Management LP | 483,000 | $3,299,000 | 0.09% |
| Fernwood Investment Management, LLC | 10,000 | $68,000 | 0.06% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1,276,833 | $8,721,000 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 120,000 | $820,000 | 0.02% |